Quarterly Outlook
Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?
John J. Hardy
Global Head of Macro Strategy
Access both platforms from your single Saxo account.
Key Stories from the past week: A Golden Milestone
Saxo
Less noise from the Oval Office this week but the tariff tit-for-tat continues. Volatility is the outcome sparking investor nerves but also presenting market opportunities. Gold is the haven winner reaching $3,000. Similar to last week, Nasdaq futures saw heavy trading on the Saxo platform as the underlying index remains under pressure (-10% ytd). This week Novo Nordisk topped the list for the most trading clients with a strong skew to the buy side at lows not seen since 2023. US inflation numbers were soft, while positive for rate cuts it is a fear for growth. More below on this week’s key stories.
Breaking $3,000
Gold reaches record $3,000 per ounce as investors flock into havens on potential growth impact of tariffs. Gold bullion-backed ETF holdings rose to about 2,687 tons which is most since Nov 2023.
Gold surges past USD 3,000 as haven demand grows
Wall Street’s “Fear Guage”
At the time of writing, VIX is at 24 and has a 1-week average of 25.96, this versus the long-term average of around 19.5. Fuelled by trade wars and market uncertainty, volatility can provide short-term fear while long-term investors should remain focused.
Volatility Explained
How to stay on track in a volatile market
EUR strength continues
Last week’s fiscal U-turn initiated the rally in Euro, and news flow continues to reinforce that rhetoric. The fundamentals indicate support could push EURUSD to a multi-year range of 1.12+, but for now the rally takes a breath.
Where does EURUSD find support?
Roche/Zealand pact
Zealand Pharma’s pact with Roche to co-develop and co-commercialise the Danish company’s experimental obesity drug Petrelintide adds another big player to the weight loss drug market. Shares in Novo Nordisk fell - 4.3% on the news to close at a 52-week low.
Roche boosts drug pipeline
Next week will again be led by political and geopolitical developments. We should have clarity over the next US spending bill while tariff spats and talks over a ceasefire in Ukraine continue. The economic calendar brings US Feb Retail Sales on Monday. Bank of Japan rate decision, EU Feb CPI and then US FOMC rate decision on Wednesday. Swiss and Bank of England rate decisions will be announced on Thursday. Scheduled earnings include several prominent Chinese companies XPeng, Tencent Music (Tues), PDD Holdings (Thurs), Nio Inc (Fri). In the US we highlight Nike, Micron, Fedex, which are all due out Thursday.
Latest Market Insights
Quarterly Outlook
-
-
Quarterly Outlook
Equity Outlook: The ride just got rougher
Charu Chanana
Chief Investment Strategist
-
Quarterly Outlook
China Outlook: The choice between retaliation or de-escalation
Charu Chanana
Chief Investment Strategist
-
Quarterly Outlook
Commodity Outlook: A bumpy road ahead calls for diversification
Ole Hansen
Head of Commodity Strategy
-
Quarterly Outlook
FX outlook: Tariffs drive USD strength, until...?
John J. Hardy
Global Head of Macro Strategy
-
Quarterly Outlook
Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges
Althea Spinozzi
Head of Fixed Income Strategy
-
Quarterly Outlook
Equity Outlook: Will lower rates lift all boats in equities?
Peter Garnry
Chief Investment Strategist
After a period of historically high equity index concentration driven by the 'Magnificent Seven' sto... -
Quarterly Outlook
Commodity Outlook: Gold and silver continue to shine bright
Ole Hansen
Head of Commodity Strategy
-
Quarterly Outlook
Macro Outlook: The US rate cut cycle has begun
Peter Garnry
Chief Investment Strategist
The Fed started the US rate cut cycle in Q3 and in this macro outlook we will explore how the rate c... -
Quarterly Outlook
FX Outlook: USD in limbo amid political and policy jitters
Charu Chanana
Chief Investment Strategist
As we enter the final quarter of 2024, currency markets are set for heightened turbulence due to US ...
Disclaimer
The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.
Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)